Special Issue "Pathogenesis and Novel Therapies of Acute Leukemias"
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 2999
Interests: acute leukemia; leukemia pathogenesis
Prevention and early detection have greatly reduced age-adjusted death rates in many types of cancer. In the United States, death rates from lung, female breast and colorectal cancers have decreased by more than 40% over the last decades, in great part due to screening and early detection. However, in contrast, death rates from acute leukemia have been relatively steady over this period, with the exception of childhood ALL where survival is > 90%. Much of the progress in acute leukemia has come from improvements in classification, monitoring and modified treatment regimens.
How can we leverage recent discoveries that have identified mutations in genes that can lead to leukemia well before leukemia occurs, or genes that are major drivers of leukemia when it occurs? Can this knowledge be used to identify individuals at risk of developing leukemia, enabling us to create diagnostic and therapeutic strategies that will prevent leukemia? Will improved subclassification of leukemia at the molecular level help novel, more targeted therapies for these diseases be successful?
This Special Issue will explore what we are learning about leukemia pathogenesis, and present progress towards new treatments that can replace “one size fits all” therapy for acute leukemia.
Dr. Gwen Nichols
Dr. Alexandra Stevens
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- acute leukemia
- leukemia pathogenesis
- diagnostic for leukemia
- therapeutic strategies for leukemia
- novel targeted therapies for leukemia
- new leukemia treatments
- replacing one-size-fits-all therapy